Vermillion investor relations

Investors

2017 News

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
11/21/17Vermillion to Present at the 29th Annual Piper Jaffray Healthcare Conference
AUSTIN, Texas, Nov. 21, 2017 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer, will provide a corporate overview at the 29th Annual Piper Jaffray Healthcare Conference, being held at the Lotte New York Palace Hotel in New York City on November 28-29, 2017. Presentation Details Date:               Wednesday, Novem... 
Printer Friendly Version
11/20/17ASPiRA Labs Announces Release of Final CMS Reimbursement Rate for OVA1
AUSTIN, Texas, Nov. 20, 2017 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (NASDAQ: VRML) and the exclusive distributor of OVA1 (Multivariate Index Assay) (MIA), and Overa (MIA2G), today announced that the Center for Medicare Services (CMS) has released the Final 2018 Clinical Lab Fee Schedule, effective January 1, 2018.  Under the new fee schedule, the price for OVA1(MIA) (code 81503) is $897.  This is a four-fold increase over the current CMS rate, and this new rate is based on the med... 
Printer Friendly Version
11/16/17Vermillion Announces Publication of Foundational Health Economics Study
Potential savings of up to $0.17 PMPM for Commercially Insured and $0.05 PMPM for Medicare AUSTIN, Texas, Nov. 16, 2017 /PRNewswire/ -- Vermillion (NASDAQ: VRML) announced today the acceptance and publication of a novel paper, "Economic Impact of Increased Utilization of Multivariate Assay Testing to Guide the Treatment of Ovarian Cancer: Implications for Payers" in the journal American Health and Drug Benefits. The paper details the base case of a budget impact model that dynamically tr... 
Printer Friendly Version
11/08/17Vermillion Reports Third Quarter 2017 Results
Conference Call at 4:30 p.m. ET Today AUSTIN, Texas, Nov. 8, 2017 /PRNewswire/-- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its financial results for the third quarter ended September 30, 2017. Valerie Palmieri, President and CEO, stated, "Third quarter inflection points and recent releases mark milestones that have been years in the making.  We believe that obtaining positive medical p... 
Printer Friendly Version
11/06/17Vermillion to Present at the Canaccord Genuity 2017 Medical Technologies & Diagnostics Forum
AUSTIN, Texas, Nov. 6, 2017 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer, will provide a corporate overview at the Canaccord Genuity 2017 Medical Technologies & Diagnostics Forum, being held at the Westin Grand Central Hotel in New York City on November 9, 2017. Presentation Details Date: Thursday, November 9 ... 
Printer Friendly Version
11/01/17ASPiRA Labs Announces a Major Coverage Milestone - A 27% Increase in Covered Lives for OVA1
AUSTIN, Texas, Nov. 1, 2017 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (NASDAQ: VRML) and the exclusive distributor of OVA1 (Multivariate Index Assay) (MIA), today announced that it has substantially expanded positive policy coverage with the addition of 14 key managed care providers. This positive coverage is a transition from negative policy to positive policy for many of these plans. "ASPiRA Labs has increased positive coverage for OVA1 with 14 providers totaling over 26 million liv... 
Printer Friendly Version
10/31/17ASPiRA Labs Announces OVA1 Contract with Louisiana Blue Cross Blue Shield
AUSTIN, Texas, Oct. 31, 2017 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (NASDAQ: VRML) and exclusive distributor of OVA1 (Multivariate Index Assay, or MIA), an ovarian cancer risk assessment test, today announced it has entered into an agreement with Blue Cross Blue Shield of Louisiana. "ASPiRA Labs has increased in-network coverage for OVA1 with BCBS of Louisiana," said Fred Ferrara, Chief Operating Officer of Vermillion, Inc. "The expanded agreement... 
Printer Friendly Version
10/27/17ASPiRA Labs Lands Strategic Managed Care Coverage and Medicaid Licensure for OVA1®
AUSTIN, Texas, Oct. 27, 2017 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (NASDAQ: VRML), today announced it has entered into agreements with Joint Venture Hospital Laboratories, LLC ("JVHL"), QCA Health Plan of Arkansas, Inc.  (d/b/a Qualchoice), Louisiana State Medicaid program, and Arizona State Medicaid Program to provide coverage for its in vitro diagnostic test, OVA1®. "We are pleased to expand the in-network coverage for OVA1 with the signing of ... 
Printer Friendly Version
10/25/17Vermillion to Report Third Quarter 2017 Financial Results and Host Investor Conference Call on November 8th
AUSTIN, Texas, Oct. 25, 2017 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its third quarter 2017 financial results on Wednesday, November 8, 2017, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time. Wednesday, November 8 @ 4:30pm Eastern Time Domestic: 888-417-2254 International: 719-325-4794 ... 
Printer Friendly Version
10/02/17ASPiRA Labs Announces In-Network Contract Agreement with HealthNet Federal Services for OVA1®
AUSTIN, Texas, Oct. 2, 2017 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (NASDAQ: VRML), today announced it has entered into an in-network contract agreement with HealthNet Federal Services, effective January 1, 2018.  This contract brings total TriCare coverage for ASPiRA Labs to over 9.4 million lives. "Expanding coverage with HealthNet Federal Services across the West TriCare Region is the latest expansion of coverage for OVA1 (MIA)," said Fred Ferrara, Chief Operating Officer of Verm... 
Printer Friendly Version
08/31/17Vermillion and ASPiRA Labs Kick Off Ovarian Cancer Awareness Month with 100,000th Patient Test Milestone and Ringing the Nasdaq Opening Bell
AUSTIN, Texas, Aug. 31, 2017 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML) will launch Ovarian Cancer Awareness Month by ringing the opening bell on Friday, September 1, joined by the New York City chapter of the National Ovarian Cancer Coalition. In the U.S. this year, there is estimated to be approximately 22,000 cases of ovarian cancer and more than 14,000 deaths resulting from this disease. In addition to bringing public awareness to the symptoms, pligh... 
Printer Friendly Version
08/09/17Vermillion Reports Second Quarter 2017 Results
Conference Call at 4:30 p.m. ET Today AUSTIN, Texas, Aug. 9, 2017 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its financial results for the second quarter ended June 30, 2017. Valerie Palmieri, President and CEO stated, "The second quarter was a milestone quarter as we had the highest organic quarterly product revenue and growth since the inception of our CLIA laboratory.  We were pleased to see positive ... 
Printer Friendly Version
08/04/17Vermillion Announces Date Change of Second Quarter 2017 Financial Results and Investor Conference Call
AUSTIN, Texas, Aug. 4, 2017 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will now report its second quarter 2017 financial results on Wednesday, August 9, 2017, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time. Wednesday, August 9th @ 4:30pm Eastern Time Domestic: 888-437-9274 International: 719-325-2437 ... 
Printer Friendly Version
08/01/17Vermillion to Present at the Canaccord Genuity 37th Annual Growth Conference on August 10th
AUSTIN, Texas, Aug. 1, 2017 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that Valerie Palmieri, President and Chief Executive Officer, will provide a corporate overview at the Canaccord Genuity 37th Annual Growth Conference, being held August 9-10 in Boston, Massachusetts. Presentation Details Date:                           Thursday, August 10 Time:    ... 
Printer Friendly Version
07/27/17Vermillion to Report Second Quarter 2017 Financial Results and Host Investor Conference Call on August 8th
AUSTIN, Texas, July 27, 2017 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its second quarter 2017 financial results on Tuesday, August 8, 2017, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time. Tuesday, August 8th @ 4:30pm Eastern Time Domestic: 888-437-9274 International: 719-325-2437 Confe... 
Printer Friendly Version
05/11/17Vermillion Reports First Quarter 2017 Results
Conference Call at 8:30 a.m. ET Today AUSTIN, Texas, May 11, 2017 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its financial results for the first quarter ended March 31, 2017. Valerie Palmieri, President and CEO of Vermillion, Inc., stated, "The first quarter was a milestone as the first time we have seen quarter-over-quarter and year-over-year growth in territories in which we have sales representation. ... 
Printer Friendly Version
04/26/17Vermillion to Report First Quarter 2017 Financial Results and Host Investor Conference Call on May 11
AUSTIN, Texas, April 26, 2017 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its first quarter 2017 financial results on Thursday, May 11, 2017, followed by an investor conference call and webcast at 8:30 a.m. Eastern Time. Thursday, May 11th @ 8:30am Eastern Time Domestic: 888-596-2629 International: 913-312-0678 Confere... 
Printer Friendly Version
03/30/17ASPiRA Labs Announces TriCare South Contract
AUSTIN, Texas, March 30, 2017 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (NASDAQ: VRML), today announced it has signed an in-network, contracted agreement with TriCare South for ASPiRA's U.S. FDA cleared, Centers for Medicare and Medicaid Services (CMS) covered, American College of Obstetricians and Gynecologists (ACOG) Level B recommended ovarian cancer risk assessment test, OVA1® (Multivariate Index Assay or MIA). TriCare South serves about 2.5 million beneficiaries in the states of Ala... 
Printer Friendly Version
03/29/17Vermillion Reports Fourth Quarter and Full Year 2016 Results
Conference Call at 4:30 p.m. ET Today AUSTIN, Texas, March 29, 2017 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its results for the fourth quarter and full year ended December 31, 2016. "2016 marked a pivotal year for us with our first clinical utility publication, ACOG guideline inclusion, international distribution agreements, major reimbursement progress with Medicare, positive medical policy coverage ... 
Printer Friendly Version
03/29/17Vermillion Announces Publication of Ovarian Cancer Symptoms Index Study
AUSTIN, Texas, March 29, 2017 /PRNewswire/ -- Vermillion (NASDAQ: VRML) announced today the acceptance for publication of the original research titled, "Evaluation of a Validated Biomarker Test in Combination With a Symptom Index to Predict Ovarian Malignancy," by Renata R. Urban, MD, Alan Smith, MS, Kathy Agnew, Vinicius Bonato, PhD, and Barbara A. Goff, MD, in the International Journal of Gynecological Cancer. Ovarian cancer is expected to affect over 22,0... 
Printer Friendly Version
03/15/17Vermillion to Report Fourth Quarter and Full Year 2016 Financial Results and Host Investor Conference Call on March 29, 2017
AUSTIN, Texas, March 15, 2017 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its fourth quarter and full year 2016 financial results on Wednesday, March 29, 2017, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time. Wednesday, March 29th @ 4:30pm Eastern Time. Domestic: 888-256-1035 International: 913-312-0947 ... 
Printer Friendly Version
03/06/17ASPiRA LABs Announces Provider Status with Medi-Cal Expanding OVA1® Access to Over 12 Million Beneficiaries
AUSTIN, Texas, March 6, 2017 /PRNewswire/ -- ASPiRA LABs, a Vermillion company (NASDAQ: VRML), today announced it has attained out-of-state provider status with Medi-Cal, California's Medicaid program, for OVA1®/Multivariate Index Assay (MIA). ASPiRA Labs is the sole source provider for OVA1 (MIA), an FDA cleared, ACOG recommended1 ovarian cancer risk assessment test. With ASPiRA Labs' out-of-state provider status with Medi-Cal, OVA1 (MIA) is now available to over 12 million Medi-Cal beneficiari... 
Printer Friendly Version
03/01/17ASPiRA LABs Announces Contracted In-Network Agreement with Blue Cross Blue Shield of Michigan for OVA1®
AUSTIN, Texas, March 1, 2017 /PRNewswire/ -- ASPiRA LABs, a Vermillion company (NASDAQ: VRML), today announced a major contracted agreement with Blue Cross Blue Shield of Michigan for ASPiRA's U.S. FDA cleared, American College of Obstetricians and Gynecologists (ACOG) recommended ovarian cancer risk assessment test, OVA1 (MIA). Blue Cross Blue Shield of Michigan serves over six million beneficiaries throughout Michigan and surrounding states. "We are pleased to announce our Blue Cross Blue S... 
Printer Friendly Version
02/14/17Vermillion Announces Equity Financing of $5.6 Million
AUSTIN, Texas, Feb. 14, 2017 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company, announced today that investors, including several Vermillion directors and members of management as well as certain significant stockholders, have agreed to purchase approximately $5.6 million of unregistered shares of Vermillion's common stock and warrants to purchase unregistered shares of Vermillion's common stock in a private placement. Under the terms of the private placement, V... 
Printer Friendly Version
01/09/17Vermillion Announces Reimbursement Code Updates for Overa and OVA1
AUSTIN, Texas, Jan. 9, 2017 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company, today announced that the company and its wholly owned subsidiary, ASPiRA Labs, have received a Proprietary Laboratory Analyses (PLA) code (0003U) for Overa (MIA2G), Vermillion's second-generation FDA cleared Multivariate Index Assay test for determining the risk of ovarian cancer in a woman with a diagnosed pelvic mass, from the American Medical Association's (AMA) CPT® Editorial Pane... 
Printer Friendly Version
01/04/17Vermillion and ASPiRA LABS Announce Receipt of Formal FDA Clarification Regarding Ovarian Cancer Screening Alert
AUSTIN, Texas, Jan. 4, 2017 /PRNewswire/ -- Vermillion (NASDAQ: VRML) and ASPiRA LABS, a Vermillion company, today announced the receipt of an FDA Clarification Letter regarding OVA1 (MIA) and Overa (MIA2G).  This letter (see attached) is in reference to the September 7, 2016 FDA Safety Communication advising women and their physicians against the use of ovarian cancer screening tests for asymptomatic women. In order to avoid any confusion as well... 
Printer Friendly Version

Share this page

share this page